Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
In order to stimulate excellent research and draw attention to the hospital's research activity, Oslo University Hospital reward outstanding publications every half-year.
Six research groups were awarded for their excellent papers published during the second half-year of 2018 on June 7th in the large auditorium at Ullevål sykehus. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations.
The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.
Johanna Olweus, Head of Dept of Cancer Immunology at the Institute for Cancer Research, OUS Radiumhospitalet, and Professor at the University of Oslo, was May 21 elected member of the executive board of CIMT during the CIMT 2019 conference for 900 participants in Mainz, Germany. CIMT is the largest and most influential organization for Cancer Immunotherapy in Europe, and has had major global impact in the field. The board contains of a handful of world-renowned immunologists.
Tor Erik Rusten is heading the Tumor-Host Biology research group at the Department of Molecular Cell Biology at the Institute for Cancer Research. His research on autophagy has recently (May 23rd) been presented in a feature article in popular science form, published on the Oslo University Hospital home page (in Norwegian), entitled "Autophagy - Hope or Threat to Cancer Patients?".
Radforsk is an evergreen investor focusing on companies that develop cancer treatment. Since its start-up in 1986, Radforsk has ploughed NOK 200 million of its profit back into cancer research at Oslo University Hospital. This year, four researchers will be awarded a total of NOK 4.5 million. One of them is Anette Weyergang, who will receive NOK 3.75 million over a three-year period.
From major journals, first or last author from the Institute for Cancer Research
Ali M, Foldvari Z, Giannakopoulou E, Böschen ML, Strønen E, Yang W, Toebes M, Schubert B, Kohlbacher O, Schumacher TN, Olweus J(2019) Induction of neoantigen-reactive T cells from healthy donors Nat Protoc, 14(6), 1926-1943 DOI 10.1038/s41596-019-0170-6, PubMed 31101906
Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG(2019) Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy Ann Oncol(in press) DOI 10.1093/annonc/mdz139, PubMed 31046124
Zhang B, Ayuda-Durán P, Piechaczyk L, Fløisand Y, Safont MM, Karlsen IT, Fandalyuk Z, Tadele D, van Mierlo P, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM(2019) GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells Haematologica, 104(5), e229 DOI 10.3324/haematol.2019.220533, PubMed 31040234
Lilleborge M, Falk RS, Russnes H, Sauer T, Ursin G, Hofvind S(2019) Risk of breast cancer by prior screening results among women participating in BreastScreen Norway Cancer(in press) DOI 10.1002/cncr.32330, PubMed 31206638
Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, van Dalum G, Flügen G, Garcia-Barberan V, Fijneman RJ, Castells A, Vodicka P, Lind GE, Stoecklein NH, Heitzer E, Gironella M(2019) Circulating biomarkers for early detection and clinical management of colorectal cancer Mol Aspects Med(in press) DOI 10.1016/j.mam.2019.06.002, PubMed 31189073
Vaclavikova R, Klajic J, Brynychova V, Elsnerova K, Alnaes GIG, Tost J, Kristensen VN, Rob L, Kodet R, Skapa P, Mrhalova M, Soucek P(2019) Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma Oncol Rep(in press) DOI 10.3892/or.2019.7186, PubMed 31173253